NCT04940416 is a clinical trial of Neurofit (oculometric testing) in Cirrhosis, sponsored by Stanford University.

Who is sponsoring NCT04940416?

NCT04940416 is sponsored by Stanford University.

What drugs are being tested in NCT04940416?

Interventions in NCT04940416: Neurofit (oculometric testing).

What condition does NCT04940416 study?

NCT04940416 studies Cirrhosis, Hepatic Encephalopathy.

Is NCT04940416 still recruiting?

NCT04940416 is currently terminated. Last updated 25 June 2021.

Last reviewed 2021-06-25 · How we verify

NCT04940416

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

Terminated Last updated 25 June 2021

What this trial tests

trial testing Neurofit (oculometric testing) in Cirrhosis in 48 participants. Terminated before completion.

Timeline

31 August 2017

Primary endpoint
17 June 2021

17 June 2021

Quick facts

Lead sponsor	Stanford University
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	48
Start date	31 August 2017
Primary completion	17 June 2021
Estimated completion	17 June 2021
Sites	1 location across United States

Drugs / interventions tested

Neurofit (oculometric testing)

Conditions studied

Cirrhosis — all drugs for Cirrhosis →
Hepatic Encephalopathy — all drugs for Hepatic Encephalopathy →

Sponsor

Stanford University

Who can join

Adults 18 to 65, any sex, with Cirrhosis or Hepatic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study involves utilizing a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing in patients with liver cirrhosis to see if the presence of advance liver disease influences eye movement metrics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cirrhosis

Currently open trials in the same condition.

NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04940416 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 25 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04940416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing